![Health / Biology / Russian Venture Company / Tuberculosis treatment / Extensively drug-resistant tuberculosis / Multi-drug-resistant tuberculosis / Skolkovo Foundation / Skolkovo innovation center / Tuberculosis / Antibiotic-resistant bacteria / Medicine Health / Biology / Russian Venture Company / Tuberculosis treatment / Extensively drug-resistant tuberculosis / Multi-drug-resistant tuberculosis / Skolkovo Foundation / Skolkovo innovation center / Tuberculosis / Antibiotic-resistant bacteria / Medicine](https://www.pdfsearch.io/img/f084c73e3831319acd802e1dab6f8bdd.jpg) Date: 2012-12-19 07:40:08Health Biology Russian Venture Company Tuberculosis treatment Extensively drug-resistant tuberculosis Multi-drug-resistant tuberculosis Skolkovo Foundation Skolkovo innovation center Tuberculosis Antibiotic-resistant bacteria Medicine | | PRESS RELEASE 19 December 2012, Moscow and Rockville, MD, USA Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SAdd to Reading ListSource URL: www.sequella.comDownload Document from Source Website File Size: 110,69 KBShare Document on Facebook
|